Clinical trials: NASH
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD
- Trial name
- NCT06176079
- Testing
- Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Michael Ohliger, MD PhD
Non-alcoholic Steatohepatitis (NASH)
FTIH of ECC4703 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
- Trial name
- NCT05552274
- Testing
- ECC4703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Non Alcoholic Fatty Liver, Obesity
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind…
- Trial name
- NCT05523024
- Testing
- Probiotic, Berberine, Probiotc and Berberine
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Poznan University of Medical Sciences
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04669470
- Testing
- bariatric endoscopy, mainly intragastric baloons, plication of stomach too
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University of Ostrava
Non-alcoholic Fatty Liver Disease
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in…
- Trial name
- LIGHT-ON (NCT02147925)
- Testing
- Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Nonalcoholic Steatohepatitis (NASH)
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.
- Trial name
- NCT04913090
- Testing
- XZP-5610 Tablet (for Part A), XZP-5610 Tablet (for Part B), XZP-5610 Tablet （for "Part C1"）
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Obesity, Obesity, Abdominal
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in…
- Conditions
- Obesity, Obesity, Abdominal, NAFLD
- Trial name
- BRAVO (NCT05647915)
- Testing
- Berberine plus lifestyle intervention
- Where
- China
- Volunteers
- 337 people
- Sponsor
- China National Center for Cardiovascular Diseases
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Dairy Protien Rich Diet for NAFLD Patients
The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, Caseins, Whey
- Trial name
- DAIPRO-NAFLD (NCT04841915)
- Testing
- High-Protein Diet, Clinical dietician, Weight loss
- Where
- 2 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease
Calisthenics Versus High Intensity Interval Training in NAFL
According to sample size calculation and after achieving the inclusion criteria, sixty patients with non-alcoholic fatty liver (NAFL) of both genders will be enrolled in this study and their ages will be ranged from30s-40s; they…
- Trial name
- NCT06032650
- Testing
- Calisthenics exercise and High intensity interval training
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients
The purpose of this study is is to use non-invasive diagnostic tests, Fibroscan and a simple blood test, to diagnose NASH in patients who undergo liver transplantation.
- Trial name
- NCT03128918
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05766449
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
This study aims to measure the effect of GLP-1 analogues on non-alcoholic fatty liver disease in patients with diabetes and/or obesity in a clinical context.
- Trial name
- GLP1_NAFLD (NCT07021443)
- Testing
- non-interventional
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitair Ziekenhuis Brussel
Healthy
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants.
- Trial name
- NCT04427917
- Testing
- PF-06835919
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-Alcoholic Fatty Liver Disease
Fatty Liver Disease in Nordic Countries
A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.
- Trial name
- FLINC (NCT04340817)
- Testing
- Proteomics, Transcriptomics, Genomics
- Where
- Denmark
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non-alcoholic Steatohepatitis
Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH
The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.
- Trial name
- NCT06297434
- Testing
- J2H-1702
- Where
- 11 sites in South Korea
- Volunteers
- 87 people
- Sponsor
- J2H Biotech
Hyperinsulinemia, Insulin Resistance
Glycemic Effect of Diazoxide in NAFLD
The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver…
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Trial name
- NCT05729282
- Testing
- Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, FreeStyle Libre Pro
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University